Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† Diagnosis of prostate cancer is primarily based on PSA testing, digital rectal examination (DRE) and imaging to select men for prostate biopsy. Moderately elevated PSA concentrations (3-10 ng/ml) have limited specificity for detection, indicating the need for more accurate biomarkers. PSA-density (PSA-D), derived from PSA level divided by prostate volume, can add value in predicting clinically significant disease.1 Several blood… Annals of Oncology December 18, 2025 Original source
Assessing How Obesity Affects the Risk of Endometrial Cancer . <br /> Nutrition and Cancer Journal December 17, 2025 Original source
Twenty-Five Years of Progress in Cancer <p>As we close out the first quarter of the twenty-first century, it isn’t hard to notice how much the world has changed since the year 2000. Smartphones. Social media. Artificial intelligence.   But how much has cancer care changed? A lot. Possibly more than you think. Treatment for many cancers now include many options beyond chemotherapy, ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/12/twenty-five-years-of-progress-in-cancer/" title="Twenty-Five… Dana-Farber Cancer Institute December 17, 2025 Original source
Germline alterations in patients with lung cancer Similar distribution of P/LP potential germline alterations in lung cancer subtypes from distinct populations by smoking status suggests increased next-generation germline sequencing may improve risk assessment. Annals of Oncology December 16, 2025 Original source
Commentary: Ultrasound Measurements of Skeletal Muscle Predict Chemotherapy Toxicity in Non-Small Cell Lung Cancer . <br /> Nutrition and Cancer Journal December 16, 2025 Original source
Letter to the Editor: Capivasertib plus abiraterone in PTEN-deficient metastatic hormone sensitive prostate cancer: CAPItello-281 phase III study The CAPItello-281 trial indicated that the addition of capivasertib to androgen deprivation therapy (ADT) + abiraterone improves radiographic progression-free survival (rPFS) compared to ADT + abiraterone + placebo in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC) (33.2 vs 25.7 months)1. Symptomatic skeletal event-free survival (SSE-FS) also showed a non-statistically significant trend (42.5 vs 37.3 months) in favor of the… Annals of Oncology December 15, 2025 Original source
Next-Generation Multicenter Studies: Using Artificial Intelligence to Automatically Process Unstructured Health Records of Patients with Lung Cancer across Multiple Institutions Manual abstraction of real-world data (RWD) from unstructured health records (HRs) remains resource-intensive, error-prone, and highly variable across institutions. Large language models (LLMs) offer a scalable alternative, but their performance in multicenter oncology settings is not fully validated. Annals of Oncology December 15, 2025 Original source
Age-related immune states and PD-1 blockade: mechanisms and strategies for the elderly <p>Aging impairs antitumor immunity and may reduce the efficacy of immune checkpoint inhibitors (ICIs). However, the underlying mechanisms remain unclear. Building on our recent findings, we review three key mechanisms of CD8<sup>+</sup> T-cell aging: elevated T-cell receptor (TCR) activation thresholds, mitochondrial dysfunction, and disruption of proteostasis. Studies in aged mice have revealed that aged naïve T cells exhibit defective priming… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Reframing adjuvant immunotherapy in melanoma: all of it starts with priming <p>Checkpoint inhibitors best perform in neoadjuvant settings for a number of solid malignancies including cutaneous melanoma as compared with adjuvant schemes. A key difference between both treatment settings is the availability of tumor antigens to continuously prime antitumor T lymphocytes. Mounting evidence indicates that priming is a function chiefly performed by a subset of dendritic cells that cross-present tumor antigens… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer Background <p>T-cell exhaustion induced by the tumor microenvironment is an important factor in posing a major challenge to effective cancer immunotherapy. Immune checkpoint inhibitors aim to reverse T-cell exhaustion. However, the effectiveness of immune checkpoint inhibitors is often limited due to their off-target effects and single targets. Herein, we attempt to identify molecular targets that can regulate the expression of… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors Background <p>Stimulator of interferon genes (STING) agonist drugs can induce expression of interferon stimulated genes (ISGs) and proinflammatory cytokine production aimed to enhance antitumor immunity. The purpose of the current study was to determine the safety, pharmacokinetic, and systemic and intratumoral pharmacodynamic properties of a novel, intravenously delivered STING agonist in client-owned dogs with cancer.</p> Methods <p>GSK856, a small-molecule dimeric… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery <p>Genetically modified cell-based therapies hold transformative potential, particularly for patients with rare cancers and ultra-rare diseases. However, progress toward regulatory approval, reimbursement, and broad patient access is often constrained by misaligned regulatory, manufacturing, and financial frameworks that do not reflect the realities of treating small populations and low-throughput production models. Drawing on a collaborative white paper and public meeting convened… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma Background <p>Programmed cell death protein-1 (PD-1) blockade has shown promising clinical efficacy in hepatocellular carcinoma (HCC), yet the underlying immunological mechanisms governing response and resistance remain unclear. This study aimed to delineate the temporal and spatial dynamics of T-cell clonotypes and their relationship with pathological response in neoadjuvant PD-1 blockade therapy in HCC. By integrating T-cell receptor (TCR) repertoire analysis… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Functional genomics for improving adoptive T-cell transfer therapies <p>Adoptive cell therapy (ACT) has shown remarkable success in the treatment of some malignancies, particularly leukemia. However, there are multiple factors that limit the durability of ACT in solid tumors, including dose-limiting toxicities, the immunosuppressive tumor microenvironment, and T-cell exhaustion. As the manufacture and preparation of adoptive T-cell therapies allows time and adequate conditions for ex vivo T-cell engineering, forward… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance Background <p>Tumor-associated macrophages (TAMs) abundantly infiltrate tumors and possess potent antitumor capabilities. "Don‘t eat me" signals like CD47 allow tumors to evade macrophages and proliferate unchecked. CD47 is upregulated in many tumors and interacts with the SIRPα expressed on macrophages to restrict effector function. Similarly, CD24 interacts with the Siglec-10 on TAMs to inhibit engulfment. Despite their potential, there is… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology <p>While immune checkpoint inhibition (ICI) has revolutionized therapy across solid tumors, resistance remains an issue. Programmed death ligand-1 immunohistochemistry has limited clinical utility, whereas tumor mutation burden and microsatellite instability are only valuable for a minority of patients and leave room for improvement. Multiomic gene signatures have enhanced prediction of immune response by incorporating interferon-gamma signaling, T-cell dysfunction and exhaustion… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer <p>Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) is a multifunctional scavenger receptor expressed on tumor-associated macrophages (TAMs). In a recent study published in the <i>Journal for ImmunoTherapy of Cancer</i>, Yu <i>et al</i> reported that CLEVER-1<sup>+</sup> TAMs accumulate in advanced gastric cancer (GC), associate with poor prognosis, and contribute to resistance to chemoimmunotherapy. CLEVER-1 blockade using bexmarilimab reprogrammed TAMs toward… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Immunomodulation of UVB-induced regulatory T cells prevents the establishment of squamous cell carcinoma Background <p>Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer in Asian, Caucasian, and Hispanic populations and its aggressive form contributes to significant morbidity and mortality. Chronic ultraviolet B (UVB) exposure is a major environmental carcinogen that drives cSCC initiation, progression, and immune evasion. Regulatory T cells (Tregs) are known mediators of UVB-induced immunosuppression; however,… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
TNF-{alpha} and IFN-{gamma} differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity Background <p>Challenges to developing immunotherapies for acute myeloid leukemia (AML) include the identification of suitable target antigens due to on-target-off-leukemia toxicity. CD70, expressed on AML bulk and leukemic stem cells with limited expression on healthy cells, has emerged as a promising target.</p> Methods <p>This study evaluated CD70 as a target for NK-cell-based immunotherapy using a sugar-engineered antibody (PF-08046040, SEA-CD70). CD70… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source
Colorectal cancer organoids drive hypoxia, TGF-{beta}, and patient-specific diversification of NK cell activation programs Background <p>Colorectal carcinoma exhibits high heterogeneity, comprising subtypes that show poor efficacy of T cell-based immunotherapies, such as programmed cell death protein 1 (PD-1) checkpoint inhibitors. Although natural killer (NK) cells are considered a promising approach for cancer immunotherapy, it remains unclear what molecular mechanisms drive NK cell activation or suppression within the tumor microenvironment. Moreover, limitations in human tumor… Journal for ImmunoTherapy of Cancer December 14, 2025 Original source